V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

PTC Therapeutics Executive Compensation (FY25)

PTCT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Matthew Klein
Latest say-on-pay support
=
June 2, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on PTC Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 5, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
PTC Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
359 figures on this page: 348 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on PTC Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Matthew Klein: $7,410,765 → $23,266,326 (214.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is PTC Therapeutics' chief executive and what were they paid?
Matthew Klein was paid $23,266,326 in total compensation as Chief Executive Officer for fiscal 2025. Klein's total moved 214.0% higher from the $7,410,765 reported for fiscal 2024.
What was PTC Therapeutics' say-on-pay result?
Shareholders recorded 98.0% support for the say-on-pay proposal at the meeting held June 2, 2026 for fiscal 2025.
Which companies are in PTC Therapeutics' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Alkermes plc, Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc. and Blueprint Medicines Corp., among others. The additional disclosed peer group includes ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Axsome Therapeutics, Inc. and Blueprint Medicines Corp., among others. The 2025 Peer Group names Axsome Therapeutics, Inc., Harmony Biosciences Holdings, Inc. and Madrigal Pharmaceuticals Corporation.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stuart Peltz
Former Chief Executive Officer
◇—◇◇◇—◇◇
Neil Almstead
Executive Vice President, Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Klein
Chief Executive Officer
◇—◇◇◇—◇◇
Stuart Peltz
Former Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Pierre Gravier
Chief Financial Officer
◇—◇◇◇—◇◇
Eric Pauwels
Chief Business Officer
◇—◇◇◇—◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Emily Hill
Executive Vice President, Chief Legal Officer
◇—◇◇——◇◇
Neil Almstead
Chief Technical Operations Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Klein
Chief Executive Officer
◇—◇◇◇—◇◇
Eric Pauwels
Chief Business Officer
◇—◇◇◇—◇◇
Neil Almstead
Chief Technical Operations Officer
◇—◇◇◇—◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Pierre Gravier
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Klein
Chief Executive Officer
◇—◇◇◇—◇◇
Eric Pauwels
Chief Business Officer
◇—◇◇◇—◇◇
Pierre Gravier
Chief Financial Officer
◇—◇◇◇—◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Neil Almstead
Chief Technical Operations Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eric PauwelsRSU◇——◇——◇
Eric PauwelsOPTION◇——◇—◇◇
Lee GoldenRSU◇——◇——◇
Lee GoldenOPTION◇——◇—◇◇
Matthew KleinOPTION◇——◇—◇◇
Matthew KleinPSU◇—◇—◇—◇
Matthew KleinRSU◇——◇——◇
Neil AlmsteadRSU◇——◇——◇
Neil AlmsteadOPTION◇——◇—◇◇
Pierre GravierRSU◇——◇——◇
Pierre GravierOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric PauwelsRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Lee GoldenOption◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Neil AlmsteadRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Pierre GravierRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Matthew KleinRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Eric Pauwels
Chief Business Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Lee Golden
Executive Vice President and Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Matthew Klein
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Neil Almstead
Chief Technical Operations Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Pierre Gravier
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Schmertzler
Board chair
◇◇◇———◇
Allan Jacobson, Ph.D
◇◇◇——◇◇
Emma Reeve
◇◇◇———◇
David P. Southwell
◇◇◇———◇
Mary Smith
◇◇◇———◇
Glenn D. Steele Jr
◇◇◇———◇
Glenn D. Steele Jr., M.D., Ph.D
◇◇◇———◇
Alethia Young
◇◇◇———◇
Stephanie S. Okey
◇◇◇———◇
Jerome B. Zeldis
◇◇◇———◇
Jerome B. Zeldis, M.D., Ph.D
◇◇◇———◇
Matthew B. Klein, M.D., M.S., F.A.C.S, Matthew B. Klein and Jessica Chutter served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options/Rsus.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Blueprint Medicines Corp. BPMC
  • Corcept Therapeutics Incorporated CORT
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Insmed, Inc. INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Pacira BioSciences, Inc. PCRX
  • Sarepta Therapeutics, Inc. SRPT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Ultragenyx Pharmaceutical Inc. RARE
Additional disclosed peer group
  • ACADIA Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corp. BPMC
  • Corcept Therapeutics Incorporated CORT
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Harmony Biosciences Holdings, Inc. HRMY
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Madrigal Pharmaceuticals Corporation MDGL
  • Sarepta Therapeutics, Inc. SRPT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Ultragenyx Pharmaceutical Inc. RARE
2025 Peer Group
  • Axsome Therapeutics, Inc. AXSM
  • Harmony Biosciences Holdings, Inc. HRMY
  • Madrigal Pharmaceuticals Corporation MDGL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 2, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 6, 2023=◇◇◇
2021June 8, 2022=◇◇◇
2020June 9, 2021=◇◇◇
2019June 10, 2020=◇◇◇
2018June 12, 2019=◇◇◇
2017June 13, 2018=◇◇◇
2016June 9, 2017=◇◇◇
2015June 10, 2016=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Matthew Klein (Chief Executive Officer), FY2025 total compensation $23,266,326 (base salary $958,500) [exec_comp, SEC accession 0001104659-26-045528, filed 2026-04-20]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when PTC Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact PTC Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where PTC Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether PTC Therapeutics' disclosed peer group is defensible, who names PTC Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
359 figures on this page: 348 cited to the filing that reported them, 11 calculated from figures it prints.
348 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001104659-26-071040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-045528
    2025 Director Compensation · Compensation Discussion and Analysis · Grants of Plan-Based Awards in 2025 · Outstanding Equity Awards at December 31, 2025 · and 1 more section
  3. 0001558370-25-008694
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001558370-24-009313
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001558370-24-005924
    Summary Compensation Table
  6. 0001070081-23-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001070081-23-000020
    Summary Compensation Table
  8. 0001558370-22-009860
  9. 0001070081-21-000020
  10. 0001070081-20-000108
  11. 0001070081-19-000038
  12. 0001070081-18-000054
  13. 0001070081-17-000104
  14. 0001104659-16-126866
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “PTC Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PTCT (accessed 2026).
Short form: data: Velarion

The paid brief for PTC Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about PTC Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers PTC Therapeutics discloses

The companies named in PTCT's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAmicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Blueprint Medicines Corp.Corcept Therapeutics IncorporatedExelixis, Inc.Halozyme Therapeutics, Inc.Insmed, Inc.Intra-Cellular Therapies, Inc.Ionis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcPacira BioSciences, Inc.Sarepta Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.Axsome Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Madrigal Pharmaceuticals Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy